🚀 VC round data is live in beta, check it out!
Axsome Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Axsome Therapeutics and similar public comparables like Eisai Co., Mankind Pharma, Huadong Medicine, Arrowhead Pharmaceuticals and more.
Axsome Therapeutics Overview
About Axsome Therapeutics
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Founded
2012
HQ
Employees
925
Website
Sectors
Financials (LTM)
EV
$9B
Axsome Therapeutics Financials
Axsome Therapeutics reported last 12-month revenue of $730M and negative EBITDA of ($129M).
In the same LTM period, Axsome Therapeutics generated $675M in gross profit, ($129M) in EBITDA losses, and had net loss of ($146M).
Revenue (LTM)
Axsome Therapeutics P&L
In the most recent fiscal year, Axsome Therapeutics reported revenue of $638M and EBITDA of ($160M).
Axsome Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $730M | XXX | $638M | XXX | XXX | XXX |
| Gross Profit | $675M | XXX | $591M | XXX | XXX | XXX |
| Gross Margin | 92% | XXX | 93% | XXX | XXX | XXX |
| EBITDA | ($129M) | XXX | ($160M) | XXX | XXX | XXX |
| EBITDA Margin | (18%) | XXX | (25%) | XXX | XXX | XXX |
| EBIT Margin | (18%) | XXX | (26%) | XXX | XXX | XXX |
| Net Profit | ($146M) | XXX | ($183M) | XXX | XXX | XXX |
| Net Margin | (20%) | XXX | (29%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Axsome Therapeutics Stock Performance
Axsome Therapeutics has current market cap of $9B, and enterprise value of $9B.
Market Cap Evolution
Axsome Therapeutics' stock price is $178.90.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9B | $9B | 3.3% | XXX | XXX | XXX | $-3.58 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAxsome Therapeutics Valuation Multiples
Axsome Therapeutics trades at 12.4x EV/Revenue multiple, and (70.1x) EV/EBITDA.
EV / Revenue (LTM)
Axsome Therapeutics Financial Valuation Multiples
As of April 11, 2026, Axsome Therapeutics has market cap of $9B and EV of $9B.
Equity research analysts estimate Axsome Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Axsome Therapeutics has a P/E ratio of (62.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9B | XXX | $9B | XXX | XXX | XXX |
| EV (current) | $9B | XXX | $9B | XXX | XXX | XXX |
| EV/Revenue | 12.4x | XXX | 14.2x | XXX | XXX | XXX |
| EV/EBITDA | (70.1x) | XXX | (56.5x) | XXX | XXX | XXX |
| EV/EBIT | (69.0x) | XXX | (54.4x) | XXX | XXX | XXX |
| EV/Gross Profit | 13.4x | XXX | 15.3x | XXX | XXX | XXX |
| P/E | (62.9x) | XXX | (50.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (96.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Axsome Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Axsome Therapeutics Margins & Growth Rates
Axsome Therapeutics' revenue in the last 12 month grew by 56%.
Axsome Therapeutics' revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.8M for the same period.
Axsome Therapeutics' rule of 40 is 50% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Axsome Therapeutics' rule of X is 131% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Axsome Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 56% | XXX | 54% | XXX | XXX | XXX |
| EBITDA Margin | (18%) | XXX | (25%) | XXX | XXX | XXX |
| EBITDA Growth | (136%) | XXX | (71%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 50% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 131% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 84% | XXX | 89% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 26% | XXX | 29% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 119% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Axsome Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Eisai Co. | XXX | XXX | XXX | XXX | XXX | XXX |
| Mankind Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Huadong Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Arrowhead Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Abivax | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Axsome Therapeutics M&A Activity
Axsome Therapeutics acquired XXX companies to date.
Last acquisition by Axsome Therapeutics was on XXXXXXXX, XXXXX. Axsome Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Axsome Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAxsome Therapeutics Investment Activity
Axsome Therapeutics invested in XXX companies to date.
Axsome Therapeutics made its latest investment on XXXXXXXX, XXXXX. Axsome Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Axsome Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Axsome Therapeutics
| When was Axsome Therapeutics founded? | Axsome Therapeutics was founded in 2012. |
| Where is Axsome Therapeutics headquartered? | Axsome Therapeutics is headquartered in United States. |
| How many employees does Axsome Therapeutics have? | As of today, Axsome Therapeutics has over 925 employees. |
| Who is the CEO of Axsome Therapeutics? | Axsome Therapeutics' CEO is Herriot Tabuteau. |
| Is Axsome Therapeutics publicly listed? | Yes, Axsome Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Axsome Therapeutics? | Axsome Therapeutics trades under AXSM ticker. |
| When did Axsome Therapeutics go public? | Axsome Therapeutics went public in 2015. |
| Who are competitors of Axsome Therapeutics? | Axsome Therapeutics main competitors are Eisai Co., Mankind Pharma, Huadong Medicine, Arrowhead Pharmaceuticals. |
| What is the current market cap of Axsome Therapeutics? | Axsome Therapeutics' current market cap is $9B. |
| What is the current revenue of Axsome Therapeutics? | Axsome Therapeutics' last 12 months revenue is $730M. |
| What is the current revenue growth of Axsome Therapeutics? | Axsome Therapeutics revenue growth (NTM/LTM) is 56%. |
| What is the current EV/Revenue multiple of Axsome Therapeutics? | Current revenue multiple of Axsome Therapeutics is 12.4x. |
| Is Axsome Therapeutics profitable? | No, Axsome Therapeutics is not profitable. |
| What is the current EBITDA of Axsome Therapeutics? | Axsome Therapeutics has negative EBITDA and is not profitable. |
| What is Axsome Therapeutics' EBITDA margin? | Axsome Therapeutics' last 12 months EBITDA margin is (18%). |
| What is the current EV/EBITDA multiple of Axsome Therapeutics? | Current EBITDA multiple of Axsome Therapeutics is (70.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.